In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi

Journal of Antimicrobial Chemotherapy

Volumn 42, Issue 6, 1998, Pages 741-745

  Johnson, E M ^a   Szekely, A ^a   Warnock, D W ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ITRACONAZOLE; VORICONAZOLE;

ABSIDIA; ANTIBIOTIC SENSITIVITY; ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; CONTROLLED STUDY; EXOPHIALA; FUNGICIDAL ACTIVITY; FUSARIUM SOLANI; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; RHIZOPUS; SPOROTHRIX SCHENCKII;

AMPHOTERICIN B; ANTIBIOTICS, ANTIFUNGAL; ANTIFUNGAL AGENTS; FUNGI; HUMANS; ITRACONAZOLE; MICROBIAL SENSITIVITY TESTS; MYCOSES; PYRIMIDINES; TRIAZOLES;

EID: 0032418143     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/42.6.741     Document Type: Article

References (18)

1. Patterson, B. E. & Coates, P. E. (1995). UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: pharmacokinetics in man. In Program and Abstracts of the Thirty-Fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1995. Abstract F78, p. 126. American Society for Microbiology, Washington, DC.
2. Denning, D. W., del Favero, A., Gluckman, E., Norfolk, D., Ruhnke, M., Yonren, S. et al. (1995). UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: clinical efficacy in acute invasive aspergillosis. In Program and Abstracts of the Thirty-Fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1995. Abstract F80, p. 126. American Society for Microbiology, Washington, DC.
3. Dupont, B., Denning, D., Lode, H., Yonren, S., Troke, P. F. & Sarantis, N. (1995). UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: clinical efficacy in chronic invasive aspergillosis. In Program and Abstracts of the Thirty-Fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1995. Abstract F81, p. 127. American Society for Microbiology, Washington, DC.
4. Troke, P. F., Brammer, K. W., Hitchcock, C. A., Yonren, S. & Sarantis, N. (1995). UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: activity in systemic candidiasis models and early clinical efficacy in oropharyngeal candidiasis. In Program and Abstracts of the Thirty-Fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1995. Abstract F73, p. 125. American Society for Microbiology, Washington, DC.
5. Barry, A. L. & Brown, S. D. (1996). In vitro studies of two triazole antifungal agents (voriconazole [UK-109,496] and fluconazole) against Candida species. Antimicrobial Agents and Chemotherapy 40, 1948-9.
6. McGinnis, M. R., Pasarell, L., Sutton, D. A., Fothergill, A. W., Cooper, C. R. & Rinaldi, M. G. (1997). In vitro evaluation of voriconazole against some clinically important fungi. Antimicrobial Agents and Chemotherapy 41, 1832-4.
7. Murphy, M., Bernard, E. M., Ishimaru, T. & Armstrong, D. (1997). Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis. Antimicrobial Agents and Chemotherapy 41, 696-8.
8. Radford, S. A., Johnson, E. M. & Warnock, D. W. (1997). In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens. Antimicrobial Agents and Chemotherapy 41, 841-3.
9. Ruhnke, M., Schmidt-Westhausen, A. & Trautman, M. (1997). In vitro activities of voriconazole (UK-109,496) against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection. Antimicrobial Agents and Chemotherapy 41, 575-7.
10. Espinel-Ingroff, A. (1998). In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. Journal of Clinical Microbiology 36, 198-202.
11. Marco, F., Pfaller, M. A., Messer, S. & Jones, R. N. (1998). In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp. Antimicrobial Agents and Chemotherapy 42, 161-3.
12. Hitchcock, C. A., Pye, G. W., Oliver, G. P. & Troke, P. F. (1995). UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: antifungal activity and selectivity in vitro. In Program and Abstracts of the Thirty-Fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1995. Abstract F72, p. 125. American Society for Microbiology, Washington, DC.
13. Manavathu, E. K., Cutright, J. L. & Chandrasekar, P. H. (1997). In vitro susceptibility of itraconazole-resistant isolates of Aspergillus fumigatus to voriconazole. Clinical Microbiology and Infection 3, Suppl. 2, 81.
14. National Committee for Clinical Laboratory Standards. (1997). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: Approved Standard M27-A. NCCLS, Wayne, PA.
15. Espinel-Ingroff, A., Bartlett, M., Bowden, R., Chin, N. X., Cooper, C., Fothergill, A. et al. (1997). Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi. Journal of Clinical Microbiology 35, 139-43.
16. Vanden Bossche, H., Koymans, L. & Moereels, H. (1995). P450 inhibitors of use in medical treatment: focus on mechanisms of action. Pharmacology and Therapeutics 67, 79-100.
17. George, D., Miniter, P. & Andriole, V. T. (1996). Efficacy of UK-109,496, a new azole antifungal agent, in an experimental model of invasive aspergillosis. Antimicrobial Agents and Chemotherapy 40, 86-91.
18. Martin, M. V., Yates, J. & Hitchcock, C. A. (1997). Comparison of voriconazole (UK-109,496) and itraconazole in prevention and treatment of Aspergillus fumigatus endocarditis in guinea pigs. Antimicrobial Agents and Chemotherapy 41, 13-6.